Miist Therapeutics is a pharmaceutical company with a mission to develop groundbreaking treatments for addiction, with a primary focus on smoking cessation. Established in 2019 and headquartered in the United States, the company aims to combat the significant health risks associated with smoking by providing effective solutions to help individuals overcome addiction. The latest investment of $50,000 in a Seed Round was secured on December 19, 2022, with participation from StartUp Health and ZeroTo510. Miist Therapeutics is dedicated to revolutionizing the approach to addiction treatment and creating a future free from its detrimental effects. Through their innovative developments, the company seeks to address the limitations of current cessation methods and empower individuals to break free from the cycle of addiction. With their laser focus on delivering impactful solutions in the healthcare and pharmaceutical industries, Miist Therapeutics is poised to make a meaningful difference in combatting addiction and improving public health.
No recent news or press coverage available for Miist Therapeutics.